 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...474475476477478479480481482483484...522523» |
- | Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 18, 2017
P2, N=38, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=194 --> 38
- ||||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial completion, Combination therapy: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 18, 2017
P3, N=572, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=194 --> 38 Active, not recruiting --> Completed
- | carboplatin / Generic mfg.
Enrollment open, Trial initiation date: NACATRINE: Neoadjuvant Carboplatin in Triple Negative Breast Cancer (clinicaltrials.gov) - May 18, 2017
P2, N=120, Recruiting, Sponsor: Barretos Cancer Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> May 2017
- | metformin / Generic mfg.
Trial suspension: Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer (clinicaltrials.gov) - May 16, 2017
P2, N=44, Suspended, Sponsor: Avera McKennan Hospital & University Health Center
Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> May 2017 Recruiting --> Suspended
- | Herceptin (trastuzumab) / Roche
Biomarker, Journal: Baseline Immunoglobulin E Levels as a Marker of Doxorubicin and Trastuzumab-Associated Cardiac Dysfunction. (Pubmed Central) - May 14, 2017
In patients receiving doxorubicin and trastuzumab, high baseline immunoglobulin E levels are associated with a lower risk of CTRCD. These novel findings suggest a new paradigm in cardio-oncology, implicating the immune system as a potential mediator of doxorubicin- and trastuzumab-induced cardiac dysfunction.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P3 trial: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 11, 2017
P3, N=310, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Prospective Study of FLT PET for Early Interim Response Assessment in Advanced Stage B-cell Lymphoma. (Pubmed Central) - May 11, 2017
(18)F-FLT PET after 1-2 cycles of chemotherapy predicts PFS and OS, and a negative (18)F-FLT iPET result may potentially help design risk-adapted therapies in patients with aggressive lymphomas. In contrast, the positive predictive value of (18)F-FLT iPET remains too low to justify changes in patient management.
- Onureg (azacitidine oral) / BMS
Trial primary completion date: A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma (clinicaltrials.gov) - May 11, 2017
P1, N=50, Recruiting, Sponsor: Celgene
In contrast, the positive predictive value of (18)F-FLT iPET remains too low to justify changes in patient management. Trial primary completion date: Apr 2017 --> Apr 2018
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial primary completion date: Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (clinicaltrials.gov) - May 11, 2017
P2, N=70, Recruiting, Sponsor: University of Cologne
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Oct 2016 --> Oct 2017
- | doxorubicin hydrochloride / Generic mfg.
Journal: Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging. (Pubmed Central) - May 11, 2017
Our data suggest that, in mice, anthracycline-induced cardiotoxicity is associated with an early increase in cardiac edema and a subsequent increase in myocardial fibrosis. The early increase in edema and subacute increase in fibrosis are strongly linked and are both predictive of late mortality.
- | Herceptin (trastuzumab) / Roche
Journal: Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations with Ejection Fraction Decline, Recovery, and Heart Failure Symptoms over 3 Years of Followup. (Pubmed Central) - May 11, 2017
Doxorubicin and trastuzumab resulted in modest, persistent declines in LVEF at 3 years. Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment open, Metastases: Uni-Koeln-1762: HD21 for Advanced Stages (clinicaltrials.gov) - May 11, 2017
P3, N=1500, Recruiting, Sponsor: University of Cologne
Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies. Not yet recruiting --> Recruiting
- | Trial primary completion date, Metastases: ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer (clinicaltrials.gov) - May 9, 2017
P2, N=58, Completed, Sponsor: Susanne Crocamo
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Jul 2016
- ||||| Tirazone (tirapazamine) / Teclison, SRI International
New P2 trial: TATE Versus TACE in Intermediate Stage HCC (clinicaltrials.gov) - May 9, 2017
P2, N=114, Not yet recruiting, Sponsor: Teclison Ltd.
- | doxorubicin hydrochloride / Generic mfg.
Enrollment change: In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma (clinicaltrials.gov) - May 8, 2017
P1, N=11, Recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Aug 2014 --> Jul 2016 N=18 --> 11
- | doxorubicin hydrochloride / Generic mfg.
Journal: Stimuli-responsive nanocomposites for magnetic targeting synergistic multimodal therapy and T1/T2-weighted dual-mode imaging. (Pubmed Central) - May 5, 2017
Anticancer drug doxorubicin hydrochloride (DOX)-loaded photothermal nanocomposite MnFe2O4@mSiO2 with magnetic targeting and T1/T2-weighted dual-mode magnetic resonance imaging of MnFe2O4 core and NIR/pH-coupling sensitive mesoporous silica shell nanocarriers was designed and synthesized successfully...The lower pH can also promote DOX releasing from mesoporous layer to enhance tumor inhibitory effect. It is confirmed that biocompatible DOX-MnFe2O4@mSiO2 nanocomposites can act as a potential multifunctional platform for effective magnetic targeting photothermal/chemo dual-modal synergistic therapies with enhanced anti-tumor efficacy and T1/T2-weighted dual modes magnetic resonance imaging (MRI) applications in vivo.
- | Trial completion, Enrollment change: PETAL: Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - May 4, 2017
P3, N=1073, Completed, Sponsor: University Hospital, Essen
It is confirmed that biocompatible DOX-MnFe2O4@mSiO2 nanocomposites can act as a potential multifunctional platform for effective magnetic targeting photothermal/chemo dual-modal synergistic therapies with enhanced anti-tumor efficacy and T1/T2-weighted dual modes magnetic resonance imaging (MRI) applications in vivo. Active, not recruiting --> Completed | N=696 --> 1073
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date, Surgery: EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - May 4, 2017
P3, N=1164, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=696 --> 1073 Trial primary completion date: Jan 2017 --> Jan 2018
- | Trial primary completion date, Surgery: Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer (clinicaltrials.gov) - May 4, 2017
P3, N=3260, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Jan 2017 --> Aug 2017
- | Trial initiation date: PHITT: Paediatric Hepatic International Tumour Trial (clinicaltrials.gov) - May 3, 2017
P3, N=300, Not yet recruiting, Sponsor: University of Birmingham
Trial primary completion date: Jan 2017 --> Aug 2017 Initiation date: Jan 2017 --> May 2017
- | anti-HER2 antibody conjugated with pegylated liposomal doxorubicin (MM-302) / Merrimack
Enrollment change, Trial withdrawal, Metastases: 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets (clinicaltrials.gov) - May 3, 2017
P, N=0, Withdrawn, Sponsor: Pamela Munster
Initiation date: Jan 2017 --> May 2017 N=10 --> 0 | Not yet recruiting --> Withdrawn
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment closed: HD17 for Intermediate Stage Hodgkin Lymphoma (clinicaltrials.gov) - May 3, 2017
P3, N=1100, Active, not recruiting, Sponsor: University of Cologne
N=10 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- || Herceptin (trastuzumab) / Roche
Trial primary completion date: Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen (clinicaltrials.gov) - May 3, 2017
P4, N=109, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2020 --> Dec 2021
- doxorubicin hydrochloride / Generic mfg., capecitabine / Generic mfg.
Trial primary completion date: Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer (clinicaltrials.gov) - May 2, 2017
P2, N=0, Withdrawn, Sponsor: University of Southern California
Trial primary completion date: Feb 2020 --> Dec 2021 Trial primary completion date: Feb 2009 --> Feb 2010
- | doxorubicin hydrochloride / Generic mfg.
Journal: External Magnetic Field Enhanced Chemo-Photothermal Combination Tumor Therapy via Iron Oxide Nanoparticles. (Pubmed Central) - May 1, 2017
Our work demonstrated that larger Fe3O4 nanoparticles, with a diameter of up to 310 nm, exhibited the best magnetic-targeting efficiency mediated by an external MF and the strongest antitumor efficacy from combination photothermal-chemotherapy. Our results could serve as a valuable reference for the future design of MNPs and their targeted delivery via the modulation of an external MF.
- | methotrexate / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Biomarker, Journal: Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. (Pubmed Central) - May 1, 2017
Children were more likely to die when inadvertently overdosed by more than 115% of the correct dose of cyclophosphamide (a HR=1.43 [0.84 to 2.43]), or doxorubicin (a HR=1.25, [0.66 to 2.35]), compared to those receiving accurate doses of the respective agent in this setting. This study codifies risk factors associated with poor outcomes for eBL patients in Africa and provides a benchmark by which to assess improvements in survival for new chemotherapeutic approaches.
- | doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Journal: Interactions of Bovine Serum Albumin with Anti-Cancer Compounds Using a ProteOn XPR36 Array Biosensor and Molecular Docking. (Pubmed Central) - May 1, 2017
In addition, the interactions between these compounds and BSA were dominated by hydrophobic forces and hydrogen bonds. Understanding the detailed information of these anti-cancer compounds can provide important insights into optimizing the interactions and activity of potential compounds during drug development.
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: LCI-SAR-STS-PEM-001: Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma (clinicaltrials.gov) - May 1, 2017
P2, N=30, Recruiting, Sponsor: Edward Kim
Understanding the detailed information of these anti-cancer compounds can provide important insights into optimizing the interactions and activity of potential compounds during drug development. Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, BRCA Biomarker: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Apr 28, 2017
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Jun 2018
- | metformin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial initiation date, Combination therapy: Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Apr 28, 2017
P1, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Mar 2017 --> Jun 2018 Initiation date: Mar 2011 --> Jul 2011
- alisertib (MLN8237) / Puma
Trial initiation date, Trial suspension: A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas (clinicaltrials.gov) - Apr 28, 2017
P1, N=24, Suspended, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Mar 2011 --> Jul 2011 Initiation date: Jul 2016 --> Oct 2016 | Recruiting --> Suspended
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - Apr 28, 2017
P2, N=43, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Jul 2016 --> Oct 2016 | Recruiting --> Suspended N=60 --> 43 | Trial primary completion date: Nov 2018 --> Feb 2017
- Venclexta (venetoclax) / Roche, AbbVie
Enrollment open: V+DA-EPOCH-R: Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Apr 28, 2017
P1, N=18, Recruiting, Sponsor: Weill Medical College of Cornell University
N=60 --> 43 | Trial primary completion date: Nov 2018 --> Feb 2017 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS
Enrollment open: NIVAHL: Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma (clinicaltrials.gov) - Apr 28, 2017
P2, N=110, Recruiting, Sponsor: University of Cologne
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Jakafi (ruxolitinib) / Incyte
Enrollment open: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Apr 28, 2017
P2, N=64, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Trial primary completion date, Metastases: ISG/AIEOP EW-1: Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma (clinicaltrials.gov) - Apr 27, 2017
P3, N=220, Recruiting, Sponsor: Italian Sarcoma Group
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Dec 2017
- | Trial initiation date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 26, 2017
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Trial primary completion date: Mar 2017 --> Dec 2017 Initiation date: Jan 2017 --> Jul 2017
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1/2 trial: Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ? 2 (clinicaltrials.gov) - Apr 26, 2017
P1/2, N=60, Recruiting, Sponsor: Prof. Dr. Clemens Schmitt
- | doxorubicin hydrochloride / Generic mfg.
Journal: Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride. (Pubmed Central) - Apr 26, 2017
In addition, in vitro cytotoxicity studies showed that blank AAP-CS-NPs did not exhibit any cytotoxic effects, while Dox AAP-CS-NPs increased the Dox·HCl cytotoxicity against MCF-7 cells as the result of significantly increased cellular uptake, compared with free Dox·HCl. Hence, the overall results obtained suggest that AAP-CS-NPs are very effective in entrapping Dox·HCl and to penetrate into tumor cells, rendering them promising carriers for hydrophilic antitumor drugs.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells. (Pubmed Central) - Apr 26, 2017
Active targeting and active targeting in combination with endo-lysosomal escape have been demonstrated to be the primary function for a nanocarrier against doxorubicin-sensitive and doxorubicin-resistant MCF-7 cells, respectively. These results indicate that the rational design of multifunctional nanocarriers for cancer therapy needs to consider the heterogeneous cancer cells and the primary function needs to be integrated to achieve effective payload delivery.
- | Trial primary completion date, Metastases: Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=15, Active, not recruiting, Sponsor: City of Hope Medical Center
These results indicate that the rational design of multifunctional nanocarriers for cancer therapy needs to consider the heterogeneous cancer cells and the primary function needs to be integrated to achieve effective payload delivery. Trial primary completion date: Mar 2017 --> Jan 2018
- | bortezomib / Generic mfg.
Trial primary completion date, Combination therapy: Modified Bortezomib-based Combination Therapy for Multiple Myeloma (clinicaltrials.gov) - Apr 25, 2017
P4, N=80, Recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Mar 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Aug 2017
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
New P3 trial: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Apr 25, 2017
P3, N=774, Not yet recruiting, Sponsor: Children's Oncology Group
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Acute Exercise Cardioprotection From Doxorubicin (clinicaltrials.gov) - Apr 24, 2017
P2, N=24, Completed, Sponsor: University of British Columbia
Trial primary completion date: Dec 2016 --> Aug 2017 Recruiting --> Completed | Initiation date: Jun 2014 --> Jan 2016 | Trial primary completion date: Dec 2015 --> May 2016
- ||||| Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed: Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A (clinicaltrials.gov) - Apr 24, 2017
P3, N=121, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Initiation date: Jun 2014 --> Jan 2016 | Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Journal: Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. (Pubmed Central) - Apr 22, 2017
Objective response was limited to patients with PI3K pathway aberration. A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.
- | doxorubicin hydrochloride / Generic mfg.
Biomarker, Journal: Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin. (Pubmed Central) - Apr 22, 2017
These findings suggest that deguelin has potent anticancer effects against pancreatic cancer and potentiates the anti-cancer effects of doxorubicin. These findings provide evidence that combined treatment with deguelin and doxorubicin represents an effective strategy for treating pancreatic cancer.
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase (clinicaltrials.gov) - Apr 21, 2017
P3, N=650, Completed, Sponsor: Rigshospitalet, Denmark
These findings provide evidence that combined treatment with deguelin and doxorubicin represents an effective strategy for treating pancreatic cancer. Recruiting --> Completed | N=1000 --> 650 | Trial primary completion date: Jun 2017 --> Mar 2016
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Apr 21, 2017
P3, N=4805, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=1000 --> 650 | Trial primary completion date: Jun 2017 --> Mar 2016 Trial primary completion date: Dec 2023 --> Dec 2016
- | methotrexate IV / Generic mfg.
New P3 trial: High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL (clinicaltrials.gov) - Apr 20, 2017
P3, N=205, Not yet recruiting, Sponsor: Chonnam National University Hospital